FDA Approves APP’s Migraine Treatment

7 October 2009 (Last Updated October 7th, 2009 18:30)

The US Food and Drug Administration (FDA) has granted approval to APP Pharmaceuticals to market sumatriptan succinate injection in two dosage strengths. Sumatriptan succinate injection is a vascular headache suppressant used for the acute treatment of migraine attacks and the acute treat

The US Food and Drug Administration (FDA) has granted approval to APP Pharmaceuticals to market sumatriptan succinate injection in two dosage strengths.

Sumatriptan succinate injection is a vascular headache suppressant used for the acute treatment of migraine attacks and the acute treatment of cluster headache episodes.

APP president and chief executive officer Thomas Silberg said that the launch of this important migraine medication in pre-filled syringes provides APP customers with a full product line of dosages and strengths for generic sumatriptan.

APP will package sumatriptan succinate injection in pre-filled syringes of 4mg (base)/0.5ml and 6mg (base)/0.5ml.

APP received FDA approval for sumatriptan succinate for injection packaged in single dose vials of 6mg/0.5ml in February 2009.